RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1

Jeehye Park, Ismael Al-Ramahi, Qiumin Tan, Nissa Mollema, Javier R. Diaz-Garcia, Tatiana Gallego-Flores, Hsiang Chih Lu, Sarita Lagalwar, Lisa Duvick, Hyojin Kang, Yoontae Lee, Paymaan Jafar-Nejad, Layal S. Sayegh, Ronald Richman, Xiuyun Liu, Yan Gao, Chad A. Shaw, J. Simon C Arthur, Harry T. Orr, Thomas F. Westbrook & 2 others Juan Botas, Huda Y. Zoghbi

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Many neurodegenerative disorders, such as Alzheimer's, Parkinson's and polyglutamine diseases, share a common pathogenic mechanism: the abnormal accumulation of disease-causing proteins, due to either the mutant protein's resistance to degradation or overexpression of the wild-type protein. We have developed a strategy to identify therapeutic entry points for such neurodegenerative disorders by screening for genetic networks that influence the levels of disease-driving proteins. We applied this approach, which integrates parallel cell-based and Drosophila genetic screens, to spinocerebellar ataxia type 1 (SCA1), a disease caused by expansion of a polyglutamine tract in ataxin 1 (ATXN1). Our approach revealed that downregulation of several components of the RAS-MAPK-MSK1 pathway decreases ATXN1 levels and suppresses neurodegeneration in Drosophila and mice. Importantly, pharmacological inhibitors of components of this pathway also decrease ATXN1 levels, suggesting that these components represent new therapeutic targets in mitigating SCA1. Collectively, these data reveal new therapeutic entry points for SCA1 and provide a proof-of-principle for tackling other classes of intractable neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalNature
Volume498
Issue number7454
DOIs
StatePublished - May 30 2013

Fingerprint

Spinocerebellar Ataxias
Neurodegenerative Diseases
Drosophila
Proteins
Genetic Testing
Mutant Proteins
Parkinson Disease
Therapeutics
Down-Regulation
Pharmacology
Ataxin-1
polyglutamine

Cite this

Park, J., Al-Ramahi, I., Tan, Q., Mollema, N., Diaz-Garcia, J. R., Gallego-Flores, T., ... Zoghbi, H. Y. (2013). RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature, 498(7454), 325-331. https://doi.org/10.1038/nature12204

RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. / Park, Jeehye; Al-Ramahi, Ismael; Tan, Qiumin; Mollema, Nissa; Diaz-Garcia, Javier R.; Gallego-Flores, Tatiana; Lu, Hsiang Chih; Lagalwar, Sarita; Duvick, Lisa; Kang, Hyojin; Lee, Yoontae; Jafar-Nejad, Paymaan; Sayegh, Layal S.; Richman, Ronald; Liu, Xiuyun; Gao, Yan; Shaw, Chad A.; Arthur, J. Simon C; Orr, Harry T.; Westbrook, Thomas F.; Botas, Juan; Zoghbi, Huda Y.

In: Nature, Vol. 498, No. 7454, 30.05.2013, p. 325-331.

Research output: Contribution to journalArticle

Park, J, Al-Ramahi, I, Tan, Q, Mollema, N, Diaz-Garcia, JR, Gallego-Flores, T, Lu, HC, Lagalwar, S, Duvick, L, Kang, H, Lee, Y, Jafar-Nejad, P, Sayegh, LS, Richman, R, Liu, X, Gao, Y, Shaw, CA, Arthur, JSC, Orr, HT, Westbrook, TF, Botas, J & Zoghbi, HY 2013, 'RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1', Nature, vol. 498, no. 7454, pp. 325-331. https://doi.org/10.1038/nature12204
Park J, Al-Ramahi I, Tan Q, Mollema N, Diaz-Garcia JR, Gallego-Flores T et al. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature. 2013 May 30;498(7454):325-331. https://doi.org/10.1038/nature12204
Park, Jeehye ; Al-Ramahi, Ismael ; Tan, Qiumin ; Mollema, Nissa ; Diaz-Garcia, Javier R. ; Gallego-Flores, Tatiana ; Lu, Hsiang Chih ; Lagalwar, Sarita ; Duvick, Lisa ; Kang, Hyojin ; Lee, Yoontae ; Jafar-Nejad, Paymaan ; Sayegh, Layal S. ; Richman, Ronald ; Liu, Xiuyun ; Gao, Yan ; Shaw, Chad A. ; Arthur, J. Simon C ; Orr, Harry T. ; Westbrook, Thomas F. ; Botas, Juan ; Zoghbi, Huda Y. / RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. In: Nature. 2013 ; Vol. 498, No. 7454. pp. 325-331.
@article{12082da868eb47c8ac97696b4fca2f96,
title = "RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1",
abstract = "Many neurodegenerative disorders, such as Alzheimer's, Parkinson's and polyglutamine diseases, share a common pathogenic mechanism: the abnormal accumulation of disease-causing proteins, due to either the mutant protein's resistance to degradation or overexpression of the wild-type protein. We have developed a strategy to identify therapeutic entry points for such neurodegenerative disorders by screening for genetic networks that influence the levels of disease-driving proteins. We applied this approach, which integrates parallel cell-based and Drosophila genetic screens, to spinocerebellar ataxia type 1 (SCA1), a disease caused by expansion of a polyglutamine tract in ataxin 1 (ATXN1). Our approach revealed that downregulation of several components of the RAS-MAPK-MSK1 pathway decreases ATXN1 levels and suppresses neurodegeneration in Drosophila and mice. Importantly, pharmacological inhibitors of components of this pathway also decrease ATXN1 levels, suggesting that these components represent new therapeutic targets in mitigating SCA1. Collectively, these data reveal new therapeutic entry points for SCA1 and provide a proof-of-principle for tackling other classes of intractable neurodegenerative diseases.",
author = "Jeehye Park and Ismael Al-Ramahi and Qiumin Tan and Nissa Mollema and Diaz-Garcia, {Javier R.} and Tatiana Gallego-Flores and Lu, {Hsiang Chih} and Sarita Lagalwar and Lisa Duvick and Hyojin Kang and Yoontae Lee and Paymaan Jafar-Nejad and Sayegh, {Layal S.} and Ronald Richman and Xiuyun Liu and Yan Gao and Shaw, {Chad A.} and Arthur, {J. Simon C} and Orr, {Harry T.} and Westbrook, {Thomas F.} and Juan Botas and Zoghbi, {Huda Y.}",
year = "2013",
month = "5",
day = "30",
doi = "10.1038/nature12204",
language = "English (US)",
volume = "498",
pages = "325--331",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7454",

}

TY - JOUR

T1 - RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1

AU - Park, Jeehye

AU - Al-Ramahi, Ismael

AU - Tan, Qiumin

AU - Mollema, Nissa

AU - Diaz-Garcia, Javier R.

AU - Gallego-Flores, Tatiana

AU - Lu, Hsiang Chih

AU - Lagalwar, Sarita

AU - Duvick, Lisa

AU - Kang, Hyojin

AU - Lee, Yoontae

AU - Jafar-Nejad, Paymaan

AU - Sayegh, Layal S.

AU - Richman, Ronald

AU - Liu, Xiuyun

AU - Gao, Yan

AU - Shaw, Chad A.

AU - Arthur, J. Simon C

AU - Orr, Harry T.

AU - Westbrook, Thomas F.

AU - Botas, Juan

AU - Zoghbi, Huda Y.

PY - 2013/5/30

Y1 - 2013/5/30

N2 - Many neurodegenerative disorders, such as Alzheimer's, Parkinson's and polyglutamine diseases, share a common pathogenic mechanism: the abnormal accumulation of disease-causing proteins, due to either the mutant protein's resistance to degradation or overexpression of the wild-type protein. We have developed a strategy to identify therapeutic entry points for such neurodegenerative disorders by screening for genetic networks that influence the levels of disease-driving proteins. We applied this approach, which integrates parallel cell-based and Drosophila genetic screens, to spinocerebellar ataxia type 1 (SCA1), a disease caused by expansion of a polyglutamine tract in ataxin 1 (ATXN1). Our approach revealed that downregulation of several components of the RAS-MAPK-MSK1 pathway decreases ATXN1 levels and suppresses neurodegeneration in Drosophila and mice. Importantly, pharmacological inhibitors of components of this pathway also decrease ATXN1 levels, suggesting that these components represent new therapeutic targets in mitigating SCA1. Collectively, these data reveal new therapeutic entry points for SCA1 and provide a proof-of-principle for tackling other classes of intractable neurodegenerative diseases.

AB - Many neurodegenerative disorders, such as Alzheimer's, Parkinson's and polyglutamine diseases, share a common pathogenic mechanism: the abnormal accumulation of disease-causing proteins, due to either the mutant protein's resistance to degradation or overexpression of the wild-type protein. We have developed a strategy to identify therapeutic entry points for such neurodegenerative disorders by screening for genetic networks that influence the levels of disease-driving proteins. We applied this approach, which integrates parallel cell-based and Drosophila genetic screens, to spinocerebellar ataxia type 1 (SCA1), a disease caused by expansion of a polyglutamine tract in ataxin 1 (ATXN1). Our approach revealed that downregulation of several components of the RAS-MAPK-MSK1 pathway decreases ATXN1 levels and suppresses neurodegeneration in Drosophila and mice. Importantly, pharmacological inhibitors of components of this pathway also decrease ATXN1 levels, suggesting that these components represent new therapeutic targets in mitigating SCA1. Collectively, these data reveal new therapeutic entry points for SCA1 and provide a proof-of-principle for tackling other classes of intractable neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=84879414055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879414055&partnerID=8YFLogxK

U2 - 10.1038/nature12204

DO - 10.1038/nature12204

M3 - Article

VL - 498

SP - 325

EP - 331

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7454

ER -